[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638443":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":30,"collaborators":7,"id":32,"slug":7,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Beatrice Casadei, MD","CONTACT","+39 051 2143480","beatrice.casadei10@unibo.it",[15],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"IRCCS Policlinico di Sant'Orsola","Bologna","Emilia-Romagna","40138","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],11.33875,44.49381,{"lat":26,"lon":25},[29],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":31,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100638443",false,"NCT07614035","Identification of the Best Treatment Pathway for Patients With Relapsed\u002FRefractory Lymphocytic B-derived Non-Hodgkin Lymphoma","Identification of the Best Treatment Pathway for Patients With Relapsed\u002FRefractory Lymphocytic B-derived Non-Hodgkin Lymphoma, Through the Identification of Prognostic Factors and Mechanisms of Resistance to Bispecific Antibody Therapy","ASCLEPIO","Inclusion Criteria:\n\n* Age≥18 years\n* Patients with histologically documented non-Hodgkin B lymphoma, with relapsed\u002Frefractory disease and candidates for BsAbs therapy (glofitamab, epcoritamab, mosunetuzumab) according to clinical indication and AIFA reimbursement criteria\n* obtaining signed and dated informed consent before the start of any screening or study-specific procedure\n\nExclusion Criteria:\n\n* Evidence of concomitant and uncontrolled diseases that could affect protocol compliance or interpretation of results.\n* Concomitant secondary neoplasm.","ALL","18 Years",{"count":42,"type":43},70,"ESTIMATED","OBSERVATIONAL","Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory\u002Frelapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and\u002For develop significant treatment toxicity.",[47],"Non-Hodgkin Lymphoma",[47,49],"bispecific antibodies","NOT_YET_RECRUITING","2026-05-22",{"date":53,"type":54},"2026-05-29","ACTUAL",{"date":56,"type":43},"2026-06-30",{"date":58,"type":43},"2028-12-31",{"name":5,"class":6},1]